Cargill has signed a multi-year platform agreement with Eagle Genomics to accelerate its microbiome and life sciences research and development across its global locations.
The partnership will enable the digital transformation of Cargill’s microbiome and life sciences R&D using Eagle Genomics’ e[datascientist] platform, which will help bring innovative products to customers faster.
With offices around the world, Eagle Genomics is particularly focused on the microbiome in the fields of sustainable agriculture and functional food.
Deploying Eagle Genomics’ AI discovery platform will initially enable Cargill to organise and synthesise microbiome data that has been collated by the company over the last decade.
“By revealing relationships between microbiome data entities and relevant multi-omics data, the platform will further enable Cargill to advance our understanding of the complex association between the microbiome and digestive and immune health in humans and animals,” said Mike Johnson, marketing director of Cargill Health Technologies.
Johnson added: “With the advanced knowledge and insights we anticipate generating from our microbiome data, the e[datascientist] will allow us to effectively build on our existing suite of health solutions and bring more relevant products to market in this exciting area of functional food.”
Anthony Finbow, CEO at Eagle Genomics, said: “We are delighted to be enabling Cargill to explore microbiome data for food and digestive health, an area which we believe will be transformed by microbiome discovery over the next decade. We look forward to a future of industry-disrupting food and nutraceutical products for humans and animals, informed by our platform.”